2022 World Conference on Lung Cancer (ePosters)-EP08.02-063. SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

EP08.02-063. SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

Back to course

Pdf Summary

Researchers from multiple institutions in China have conducted a study to evaluate the efficacy and safety of combining savolitinib and osimertinib in the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and mesenchymal epithelial transition (MET) overexpression. This combination therapy aims to overcome or delay resistance to osimertinib caused by MET overexpression.<br /><br />Savolitinib is a highly selective oral MET tyrosine kinase inhibitor (TKI) that has shown promising anti-tumor activity in patients with different types of NSCLC with MET exon 14 skipping alterations. It has been approved in China for the treatment of metastatic NSCLC with MET exon 14 skipping alterations. Osimertinib, on the other hand, is a third-generation EGFR TKI that selectively inhibits EGFR mutations.<br /><br />The study, called SANOVO, is a phase 3, double-blind, randomized trial that will enroll 320 patients in China. The participants must have untreated unresectable or metastatic NSCLC with EGFR mutation and MET overexpression. They will be randomly assigned to receive either savolitinib or placebo in combination with osimertinib. The primary endpoint of the study is progression-free survival (PFS), and secondary endpoints include objective response rate, duration of response, overall survival, and safety.<br /><br />The researchers hope that this combination therapy will provide a more effective treatment option for patients with advanced NSCLC who have both EGFR mutation and MET overexpression, which currently represents an unmet medical need. The study is sponsored by HUTCHMED Limited, and the enrollment is ongoing.<br /><br />In conclusion, the combination of savolitinib and osimertinib is being investigated in a phase 3 study for the treatment of NSCLC patients with EGFR mutation and MET overexpression. This study aims to address the clinical need for effective treatments in this patient population.

Asset Subtitle

Qing Zhou

Meta Tag

Speaker Qing Zhou

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

China

study

efficacy

safety

savolitinib

osimertinib

NSCLC

EGFR mutation

MET overexpression

combination therapy